Wall Street brokerages forecast that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce $9.06 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Conatus Pharmaceuticals’ earnings. The lowest sales estimate is $4.88 million and the highest is $10.64 million. Conatus Pharmaceuticals reported sales of $10.01 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 9.5%. The company is expected to issue its next quarterly earnings report on Wednesday, August 1st.
According to Zacks, analysts expect that Conatus Pharmaceuticals will report full-year sales of $40.26 million for the current fiscal year, with estimates ranging from $34.25 million to $47.70 million. For the next fiscal year, analysts expect that the business will post sales of $55.77 million per share, with estimates ranging from $34.00 million to $85.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Wednesday, May 2nd. The biotechnology company reported ($0.17) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.17). The firm had revenue of $9.74 million for the quarter, compared to the consensus estimate of $8.88 million. Conatus Pharmaceuticals had a negative net margin of 49.30% and a negative return on equity of 64.30%.
A number of equities research analysts have issued reports on the stock. ValuEngine cut shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, April 6th. Oppenheimer assumed coverage on shares of Conatus Pharmaceuticals in a report on Thursday, March 1st. They set a “buy” rating and a $16.00 price target for the company. SunTrust Banks decreased their price target on shares of Conatus Pharmaceuticals to $4.30 and set a “buy” rating for the company in a report on Thursday, April 5th. HC Wainwright decreased their price target on shares of Conatus Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, April 5th. Finally, Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 10th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $12.14.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CNAT. BlackRock Inc. lifted its stake in shares of Conatus Pharmaceuticals by 45.4% in the first quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock valued at $13,601,000 after buying an additional 723,413 shares during the period. MPM Asset Management LLC raised its position in Conatus Pharmaceuticals by 17.3% in the first quarter. MPM Asset Management LLC now owns 2,464,807 shares of the biotechnology company’s stock worth $14,468,000 after purchasing an additional 363,636 shares in the last quarter. American Century Companies Inc. acquired a new position in Conatus Pharmaceuticals in the first quarter worth about $643,000. Geode Capital Management LLC raised its position in Conatus Pharmaceuticals by 26.2% in the fourth quarter. Geode Capital Management LLC now owns 429,556 shares of the biotechnology company’s stock worth $1,983,000 after purchasing an additional 89,179 shares in the last quarter. Finally, Macquarie Group Ltd. raised its position in Conatus Pharmaceuticals by 116.8% in the fourth quarter. Macquarie Group Ltd. now owns 130,300 shares of the biotechnology company’s stock worth $602,000 after purchasing an additional 70,200 shares in the last quarter. Institutional investors and hedge funds own 40.56% of the company’s stock.
CNAT stock opened at $5.14 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.41 and a quick ratio of 2.41. Conatus Pharmaceuticals has a 52-week low of $3.22 and a 52-week high of $7.95. The stock has a market cap of $133.18 million, a price-to-earnings ratio of -8.43 and a beta of 1.29.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.